Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842418 | 0.95 | C1S (0.61) | C1S | |
| SCHEMBL5840988 | 0.94 | C1S (0.68) | C1S | |
| SCHEMBL5840191 | 0.93 | C1S (0.68) | C1S | |
| SCHEMBL4194725 | 0.93 | C1S (0.76) | C1S | |
| SCHEMBL13946307 | 0.93 | C1S (0.68) | C1S | |
| SCHEMBL5840493 | 0.92 | C1S (0.77) | C1S | |
| SCHEMBL5840388 | 0.90 | C1S (0.78) | C1S | |
| SCHEMBL5841405 | 0.90 | C1S (0.69) | C1S | |
| SCHEMBL5841055 | 0.89 | C1S (0.63) | C1S | |
| SCHEMBL5840178 | 0.89 | C1S (0.70) | C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1644046-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005002627-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004031-A1 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004031-A1 | Conjugated complement cascade inhibitors | C9, CFH, CFB | C1S 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.